Leerink analyst Marc Goodman lowered his price target for Neurocrine to $84 from $110, while reiterating a Market Perform rating on the shares. In Tourette syndrome, the analyst removed his sales forecasts due to the negative readout of T-Force GOLD and in Tardive dyskinesia, he adjusted his peak sales estimates from about $2.5B to $2.0B.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.